These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21925171)

  • 1. EGFR-targeted therapy.
    Vecchione L; Jacobs B; Normanno N; Ciardiello F; Tejpar S
    Exp Cell Res; 2011 Nov; 317(19):2765-71. PubMed ID: 21925171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
    Hawkes E; Cunningham D
    Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.
    Okamoto I
    FEBS J; 2010 Jan; 277(2):309-15. PubMed ID: 19922468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted therapy in first line treatment of RAS wild type colorectal cancer.
    Formica V; Roselli M
    World J Gastroenterol; 2015 Mar; 21(10):2871-4. PubMed ID: 25780283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.
    Mitsudomi T; Yatabe Y
    FEBS J; 2010 Jan; 277(2):301-8. PubMed ID: 19922469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer.
    Lopez-Chavez A; Carter CA; Giaccone G
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1305-14. PubMed ID: 19943202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
    Santini D; Galluzzo S; Gaeta L; Zoccoli A; Riva E; Ruzzo A; Vincenzi B; Graziano F; Loupakis F; Falcone A; Muda AO; Tonini G
    J Clin Oncol; 2011 Mar; 29(8):e206-7; author reply e208-9. PubMed ID: 21263083
    [No Abstract]   [Full Text] [Related]  

  • 10. Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.
    Bösmüller H; Kranewitter W; Webersinke G; Rumpold H; Hackl M; Fend F
    Pathol Res Pract; 2011 Jun; 207(6):399-402. PubMed ID: 21536390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.
    Chu E
    Oncology (Williston Park); 2014 Feb; 28(2):96. PubMed ID: 24701695
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II
    Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation.
    Yin P; Qiu Y; Li Q
    Int J Colorectal Dis; 2013 May; 28(5):733-4. PubMed ID: 22752244
    [No Abstract]   [Full Text] [Related]  

  • 16. [EGFR/HER1: a target life].
    Viel E; Curtit E; Mansi L; Vignot S
    Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutation: should we test for it, and does it matter?
    Roberts PJ; Stinchcombe TE
    J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
    Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
    J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.